Navigation Links
PDL BioPharma Announces Second Quarter 2009 Financial Results
Date:7/30/2009

INCLINE VILLAGE, Nev., July 30 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today reported financial results for the second quarter ended June 30, 2009.

Total revenues from continuing operations for the second quarter of 2009 were $125.9 million, an 18 percent increase from $106.5 million for the same period in 2008. The increase was due primarily to royalty revenues driven by higher product sales of Avastin(R), and Lucentis(R), which are marketed by Genentech, Inc., a subsidiary of F. Hoffman-LaRoche Ltd., and sales of Tysabri(R), which is marketed by Elan Corporation Plc. and Biogen Idec Inc. Royalty revenues are based on first quarter 2009 product sales by PDL's licensees and include $18.9 million for Synagis(R), which is marketed by MedImmune, Inc. Also included in the second quarter revenue was the second and final installment of $12.5 million from Alexion Pharmaceuticals, Inc. based on the companies' December 2008 settlement and license agreement. When compared with 2008, royalty revenue for foreign sourced sales was negatively impacted by changes in foreign exchange rates; approximately 50 percent of underlying product sales is in currencies other than U.S. dollars.

"We have seen significant increases in sales of Tysabri and other products in our licensing portfolio, demonstrating that these products are fulfilling the promise of the underlying humanization technology," said John McLaughlin, president and chief executive officer of PDL BioPharma. "We paid our first post spin-off dividend to stockholders this quarter, and expect to pay the second dividend on October 1 as we continue to optimize our assets to benefit stockholders."

Total general and administrative expenses from continuing operations in the second quarter of 2009 were $5.
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. PDL BioPharma to Announce Second Quarter 2009 Financial Results and Hold Conference Call July 30, 2009
2. DOR BioPharma Appoints Christopher P. Schnittker, CPA, as Vice President of Administration and Controller
3. AlphaRx and Gaia BioPharma Report Positive Efficacy Results in a Pre-Clinical Trial of GAI-122 Injectable Nano-emulsion for Post-operative Delirium
4. Helix Biopharma Corp. Begins Trading on the OTCQX International Market Listing as HXBPF
5. Sinobiopharma Receives Trademark Approval and Authentication From Chinese Government For Its Tai Drug Series
6. Keryx Biopharmaceuticals Inc. Regains Compliance With NASDAQ Listing Requirements
7. AlphaRx and Gaia BioPharma Provide GAI-122 Development Update
8. PDL BioPharma Announces Record Date for October 1 Dividend Payment
9. Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance
10. SAFE-BioPharma Webinar Featuring ARX's Digital Signatures Combined with Microsoft SharePoint for Bio-Pharma industry
11. Prix Galien USA Now Accepting Nominations for Premiere Biopharmaceutical Industry Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 24, 2014 (HealthDay News) -- A lab technician ... may have been exposed to the Ebola virus in ... And up to a dozen other lab workers are ... Wednesday afternoon. The possible exposure occurred Monday when ... sample of the potentially lethal virus to another CDC ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 Gluten, a ... on those who have an intolerance to gluten, causing ... gas, bloating, migraine headaches, joint pain and fatigue. For ... diet plans that deliver safe and fast weight ... that trigger a gluten allergy reaction. These gluten free ...
(Date:12/24/2014)... Jacksonville, Florida (PRWEB) December 24, 2014 The ... a safer place to raise families. In-Vest USA ... those who protect us – our first responders. Today, these ... law enforcement officers by providing them with body armor through ... like the tragic shootings that happened this past week in ...
(Date:12/24/2014)... Dallas, Texas (PRWEB) December 24, 2014 ... COC Industry is a professional and in-depth research ... the report introduces COC basic information, including its ... policy analysis, news analysis, etc. This report also ... structure etc. Production is separated by regions, technology ...
(Date:12/24/2014)... FL (PRWEB) December 24, 2014 There’s a ... days. With the Republican Party now in control of the ... again for the Affordable Care Act. A lawsuit has been ... delays of certain provisions in the ACA have resulted in ... Also, a Supreme Court hearing will take place to weigh ...
Breaking Medicine News(10 mins):Health News:CDC Monitors Lab Worker for Possible Ebola Exposure 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 3Health News:The Healthy Home Company and In-Vest USA Team Up to Save the Lives of Law Enforcement 2Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 2Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 3Health News:Steven Gerst MD Discusses How, Amid Political Opposition, Court Challenges, and a New Open Enrollment Period, the Affordable Care Act still Relies on Health Informatics 2Health News:Steven Gerst MD Discusses How, Amid Political Opposition, Court Challenges, and a New Open Enrollment Period, the Affordable Care Act still Relies on Health Informatics 3
... Travel Advantage Network , one of the nation,s ... Susan G. Komen for the Cure , the global leader ... pin sales and a Jeans Day, where employees purchase the ... employees raised $729 for Susan G. Komen for the Cure, ...
... 22 McAuley Ministries, the new grant-making arm of ... first grant... and the recipient is the YMCA of ... the construction of a green rooftop terrace for the ... new Thelma Lovette YMCA touches several of McAuley Ministries ...
... Aurora Health Care announced today that,the physicians ... join Aurora Medical Group. , ... Paul,Guzzetta, M.D., and Mark Plumb, M.D. All are board-certified ... specializes and is,board-certified in the treatment of sleep disorders. ...
... In the year following Hurricane Katrina, the health of ... of a national sample of older adults not affected ... researchers at the Johns Hopkins Bloomberg School of Public ... most powerful and deadliest hurricanes in U.S. history. Hurricane ...
... the founder and longtime director of the HIV advocacy/education ... Institute of Allergy and Infectious Diseases (NIAID) Director,s Special ... against HIV/AIDS. , Mr. Delaney in 1985 ... public policy information and advocacy organization based in San ...
... , Montreal, January 22, 2009 The ... that preventive treatment with high doses of inhaled corticosteroids ... asthma attacks triggered by colds. Dr. Francine Ducharme, assistant ... Center and a pediatrics professor at the Universit de ...
Cached Medicine News:Health News:Grassroots Group Gets Travel Advantage Network Support 2Health News:YMCA of Greater Pittsburgh Receives $500,000 from McAuley Ministries for New Hill YMCA Roof 2Health News:YMCA of Greater Pittsburgh Receives $500,000 from McAuley Ministries for New Hill YMCA Roof 3Health News:Midwest Pulmonary and Critical Care Associates Will Join Aurora Medical Group 2Health News:Decline in health among older adults affected by Hurricane Katrina 2Health News:NIAID honors AIDS activist Martin Delaney 2Health News:New treatment reduces severity of asthma attacks in preschoolers 2
(Date:12/22/2014)... MONMOUTH JUNCTION, N.J. , Dec. 22, 2014 ... immunotherapy company marketing its CytoSorb® blood purification technology ... cardiac surgery patients in 28 countries worldwide, today ... Di Russo , MD, FACS, as its Senior ... 2015. Dr. Di Russo ...
(Date:12/22/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ... Self-monitoring Blood Glucose Market" report to their offering. ... This market insight focuses on the developments in the ... States . Reimbursement analysis and the effects of ... more than 73 SMBG meters have been performed, based ...
(Date:12/22/2014)... , Dec. 22, 2014  ConvaTec, a privately-held medical ... has been appointed Interim Chief Executive Officer of the ... succeeds Ken Berger .  "The Board of Directors ... leading ConvaTec over the past three years," said ... Directors.  "We are confident that the company is well ...
Breaking Medicine Technology:CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5US Self-monitoring Blood Glucose Market 2ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2
... received 510(k) clearance from the U.S. Food and Drug ... spot scanning. Spot scanning is a proton therapy delivery ... the tumor by using thousands of small individual beamlets ... Intensity Modulated Proton Therapy (IMPT). XiO, Elekta,s ...
... 3, 2010 Halozyme Therapeutics, Inc. (Nasdaq: ... commercializing products targeting the extracellular matrix , today ... serve as president and CEO, effective immediately. Jonathan E. ... of the board of directors to pursue other opportunities. ...
Cached Medicine Technology:Elekta Receives FDA 510(k) Clearance for XiO Software to Plan Spot Scanning for Proton Therapy 2Halozyme Therapeutics Realigns Management 2Halozyme Therapeutics Realigns Management 3